C4 Therapeutics has filed a patent for Degronimers, which are compounds that can be linked to a targeting ligand for a specific protein to induce its degradation in vivo. The invention also includes Degrons that can be used to treat disorders related to cereblon or an Ikaros family protein. Methods of use, compositions, and preparation of these compounds are also provided. GlobalData’s report on C4 Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights C4 Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on C4 Therapeutics, cancer treatment biomarkers was a key innovation area identified from patents. C4 Therapeutics's grant share as of September 2023 was 11%. Grant share is based on the ratio of number of grants to total number of patents.

Compound with e3 ubiquitin ligase targeting moieties for protein degradation

Source: United States Patent and Trademark Office (USPTO). Credit: C4 Therapeutics Inc

The patent application (Publication Number: US20230279023A1) describes a compound of Formula 1. The compound is a novel chemical entity that has potential applications in various fields. The formula represents the molecular structure of the compound, which is not disclosed in the summary. The compound is claimed to have certain properties or characteristics that make it unique and valuable.

The compound of Formula 1 is likely to have significant implications in the field it is intended for. The patent application suggests that the compound possesses specific features or functionalities that set it apart from existing compounds. These unique properties could potentially make it useful in various applications, such as pharmaceuticals, materials science, or other industries.

However, without further information on the specific details of the compound, its potential applications, or the claimed properties, it is challenging to provide a comprehensive analysis. The patent application does not disclose any experimental data or examples to support the claims made about the compound. Therefore, it is crucial to await further information or research to determine the actual value and potential of the compound.

In conclusion, the patent application (Publication Number: US20230279023A1) introduces a compound of Formula 1, which is claimed to have unique properties or characteristics. The compound's potential applications and value are not explicitly stated in the summary, as further information or research is required to assess its actual potential. It is important to note that the claims made in the patent application should be supported by experimental data or examples to validate the compound's properties and applications.

To know more about GlobalData’s detailed insights on C4 Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies